{"id":"W2012876387","doi":"10.1038/leu.2012.329","title":"PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"ca_institutions":"Toronto General Hospital; York University; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Chronic lymphocytic leukemia; CD5; Peroxisome proliferator-activated receptor; Downregulation and upregulation; Biology; Lipoprotein lipase; Cancer research; Peroxisome proliferator-activated receptor alpha; Internal medicine; Endocrinology; Receptor; Leukemia; Nuclear receptor; Immunology; Adipose tissue; Antibody; Medicine; Transcription factor; Biochemistry","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008472648,0.0005906568,0.0008714607,0.0002843724,0.0002778729,0.00007442373,0.0005030896,0.0005031193,0.00164985],"category_scores_gemma":[0.0002420004,0.0005128389,0.0005175643,0.0006185614,0.0003125678,0.0003795462,0.0001929398,0.0005021096,0.001618085],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.3263483,"about_ca_system_score_gemma":0.07328864,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007998658,"about_ca_topic_score_gemma":0.0000151035,"domain_scores_codex":[0.9951878,0.0000875258,0.000707647,0.0007625464,0.0009869284,0.002267505],"domain_scores_gemma":[0.9968123,0.0004842683,0.0001856436,0.001370373,0.0002463011,0.0009011526],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01005469,0.0008309858,0.009482462,0.01278271,0.005956765,0.0006450239,0.01411716,0.002633268,0.1053078,0.02205008,0.6217771,0.194362],"study_design_scores_gemma":[0.06230551,0.001638163,0.001574186,0.000451,0.0007057678,0.001538072,0.0002634699,0.1836595,0.1031313,0.001477309,0.6419689,0.001286844],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9272289,0.03038934,0.007391209,0.0009065493,0.002052718,0.005337677,0.000128436,0.0009873757,0.02557778],"genre_scores_gemma":[0.9737119,0.0003273794,0.002614441,0.003306426,0.002839292,0.000562911,0.0001200434,0.0002160366,0.01630158],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2530596,"threshold_uncertainty_score":0.9997323,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03439344377669197,"score_gpt":0.3255027107052507,"score_spread":0.2911092669285588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}